I’m a HUGE fan of basic research. What I dislike is overhyped conclusions.

“While these two viruses are in a viral lineage distinct from SARS-CoV-1 and -2, the RBD from one virus, Khosta 2, was capable of using human ACE2 to facilitate cell entry. Viral pseudotypes with a recombinant, SARS-CoV-2 spike encoding for the Khosta 2 RBD were resistant to both SARS-CoV-2 monoclonal antibodies and serum from individuals vaccinated for SARS-CoV-2.”

It’s not very interesting to randomly test the cross reactivity of antibodies to unrelated viruses. It’s much more important to understand the receptor:RBD dynamics. As a former journal editor at a different journal, I’m surprised this got into PLoS Pathogens.